Literature DB >> 27663119

Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease.

Ruth Ann Marrie1, John R Walker2, Lesley A Graff2, Lisa M Lix3, James M Bolton4, Zoann Nugent5, Laura E Targownik6, Charles N Bernstein7.   

Abstract

OBJECTIVES: Comorbid depression and anxiety are common in inflammatory bowel disease (IBD), but few population-based estimates of the burden of depression and anxiety exist. Methods to support population-based studies are needed. We aimed to test the performance of administrative case definitions for depression and anxiety in IBD and to understand what the prevalence estimated using such definitions reflects.
METHODS: We linked administrative (health claims) data from the province of Manitoba, Canada with clinical data for 266 persons in the Manitoba IBD Cohort Study. We compared the performance of administrative case definitions for depression and anxiety with (a) diagnoses of depression and anxiety as identified based on the Composite International Diagnostic Interview (CIDI), which identifies disorders meeting formal diagnostic criteria, and (b) participant report of physician-diagnosed depression or anxiety.
RESULTS: Administrative definitions for depression showed moderate agreement with the CIDI (κ=0.39-0.42). Agreement was higher with participant report of physician-diagnosed depression (κ=0.54). The lifetime prevalence of depression was 29.3% based on the CIDI, 17.7% based on participant report of physician-diagnosed depression, and 21.8-22.5% based on administrative data. Compared to the CIDI, administrative definitions for anxiety showed fair agreement (κ=0.21-0.25). The lifetime prevalence of anxiety was 31.2% based on the CIDI, 9.7% based on participant report of physician-diagnosed anxiety, and 24.4-31.9% based on administrative data.
CONCLUSIONS: Administrative data may be used for population-level surveillance of depression and anxiety in IBD, although they will not capture undiagnosed or untreated cases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Administrative data; Anxiety; Depression; Inflammatory bowel disease; Population-based; Validation

Mesh:

Year:  2016        PMID: 27663119     DOI: 10.1016/j.jpsychores.2016.08.014

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  16 in total

1.  Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Michael D Kappelman; Christopher F Martin; Joshua R Korzenik; Seth D Crockett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

2.  The Burden of Hospital Readmissions among Pediatric Patients with Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Christopher F Martin; Seth D Crockett; Joshua R Korzenik; Michael D Kappelman
Journal:  J Pediatr       Date:  2017-10-14       Impact factor: 4.406

3.  Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease.

Authors:  Charles N Bernstein; Carol A Hitchon; Randy Walld; James M Bolton; Jitender Sareen; John R Walker; Lesley A Graff; Scott B Patten; Alexander Singer; Lisa M Lix; Renée El-Gabalawy; Alan Katz; John D Fisk; Ruth Ann Marrie
Journal:  Inflamm Bowel Dis       Date:  2019-01-10       Impact factor: 5.325

4.  Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.

Authors:  Usama Jazzar; Shan Yong; Zachary Klaassen; Jinhai Huo; Byron D Hughes; Edgar Esparza; Hemalkumar B Mehta; Simon P Kim; Douglas S Tyler; Stephen J Freedland; Ashish M Kamat; Dwight V Wolf; Stephen B Williams
Journal:  Cancer       Date:  2018-04-16       Impact factor: 6.860

5.  The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study.

Authors:  Kendiss Olafson; Ruth Ann Marrie; James M Bolton; Charles N Bernstein; O Joseph Bienvenu; Maia S Kredentser; Sarvesh Logsetty; Dan Chateau; Yao Nie; Marcus Blouw; Tracie O Afifi; Murray B Stein; William D Leslie; Laurence Y Katz; Natalie Mota; Renée El-Gabalawy; Murray W Enns; Christine Leong; Sophia Sweatman; Jitender Sareen
Journal:  Intensive Care Med       Date:  2021-09-08       Impact factor: 17.440

6.  The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study.

Authors:  Charles N Bernstein; Carol A Hitchon; Randy Walld; James M Bolton; Lisa M Lix; Renée El-Gabalawy; Jitender Sareen; Alexander Singer; Alan Katz; James Marriott; John D Fisk; Scott B Patten; Ruth Ann Marrie
Journal:  Inflamm Bowel Dis       Date:  2021-08-19       Impact factor: 5.325

7.  Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data.

Authors:  Ruth Ann Marrie; Randy Walld; James M Bolton; Jitender Sareen; John R Walker; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; John D Fisk; Charles N Bernstein
Journal:  BMC Res Notes       Date:  2017-11-25

8.  Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis.

Authors:  Ruth Ann Marrie; Carol A Hitchon; Randy Walld; Scott B Patten; James M Bolton; Jitender Sareen; John R Walker; Alexander Singer; Lisa M Lix; Renée El-Gabalawy; Alan Katz; John D Fisk; Charles N Bernstein
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-05-21       Impact factor: 4.794

9.  Association between delirium in the intensive care unit and subsequent neuropsychiatric disorders.

Authors:  Kyla N Brown; Andrea Soo; Peter Faris; Scott B Patten; Kirsten M Fiest; Henry T Stelfox
Journal:  Crit Care       Date:  2020-07-31       Impact factor: 9.097

10.  High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases.

Authors:  Irene Marafini; Lucia Longo; Damun Miri Lavasani; Rodolfo Rossi; Silvia Salvatori; Federica Pianigiani; Emma Calabrese; Alberto Siracusano; Giorgio Di Lorenzo; Giovanni Monteleone
Journal:  J Clin Med       Date:  2020-05-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.